(Q40172905)

18 September 2017

1 reference

title

Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects (English)

1 reference

18 September 2017

1 reference

1 reference

D P Zipes

1

1 reference

18 September 2017

E N Prystowsky

series ordinal

2

1 reference

18 September 2017

J J Heger

series ordinal

3

1 reference

18 September 2017

language of work or name

English

0 references

publication date

1 April 1984

1 reference

Journal of the American College of Cardiology

18 September 2017

1 reference

18 September 2017

3

1 reference

18 September 2017

4

1 reference

18 September 2017

1059-1071

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

18 September 2017

1 reference

7 January 2021

Clinical efficacy of amiodarone as an antiarrhythmic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

New antiarrhythmic agents: amiodarone, aprindine, disopyramide, ethmozin, mexiletine, tocainide, verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Electropharmacology of antiarrhythmic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

The effects of amiodarone on the sinus node activity of the rabbit heart

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Amiodarone blocks inactivated cardiac sodium channels

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Amiodarone: Historical development and pharmacologic profile

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Class 3 antiarrhythmic action in man. Observations from monophasic action potential recordings and amiodarone treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

The adrenergic antagonism of amiodarone

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Studies of amiodarone during experimental myocardial infarction: beneficial effects on hemodynamics and infarct size

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Effects of amiodarone on cardiac and coronary hemodynamics and on myocardial metabolism in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Hemodynamic effects of intravenous amiodarone in patients with depressed left ventricular function and recurrent ventricular tachycardia.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Efficacy and safety of long-term amiodarone in treatment of cardiac arrhythmias: dosage experience

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Efficacy of chronic amiodarone therapy in patients with variant angina pectoris and inhibition of ergonovine coronary constriction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Amiodarone pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Relationships between amiodarone dosage, drug concentrations, and adverse side effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Amiodarone kinetics after oral doses

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Pharmacokinetics of amiodarone after intravenous and oral administration

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Amiodarone dosing: a proposal based on its pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Clinical antiarrhythmic effects of amiodarone in patients with resistant paroxysmal tachycardias

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Efficacy of amiodarone for refractory supraventricular tachyarrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Side effects and possible contraindications of amiodarone use.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Ten years of experience with amiodarone

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Effect of amiodarone in paroxysmal supraventricular tachycardia with or without Wolff-Parkinson-White syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Use of procainamide in patients with the Wolff-Parkinson-White syndrome to disclose a short refractory period of the accessory pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Electrophysiological assessment of amiodarone in treatment of resistant supraventricular arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Amiodarone in the treatment of cardiac arrhythmias in children: one hundred thirty-five cases

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Clinical efficacy of amiodarone in treatment of recurrent ventricular tachycardia and ventricular fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: arrhythmia previously induced by quinidine and disopyramide

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Amiodarone-induced ventricular tachycardia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Amiodarone-induced polymorphous ventricular tachycardia

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Amiodarone for control of sustained ventricular tachyarrhythmia: clinical and electrophysiologic effects in 51 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Electrophysiologic effects of chronic amiodarone therapy in patients with ventricular arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening ventricular arrhythmias: potent suppression of spontaneously occurring tachyarrhythmias versus inconsistent abolition of induced ventricular tachy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Role of programmed stimulation in assessing vulnerability to ventricular arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Determinants of survival in patients with ventricular tachyarrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Neuromyopathy during chronic amiodarone treatment. A case report

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Dangers of amiodarone and anticoagulant treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

The potentiation of warfarin anticoagulation by amiodarone

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Drug interactions with amiodarone

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Interaction between warfarin sodium and amiodarone

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Amiodarone increases plasma digoxin concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Amiodarone and amiodarone plus digitalis in the treatment of paroxismal supraventricular reciprocating tachyarrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Dangerous interaction between amiodarone and quinidine

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Possible amiodarone-aprindine interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Amiodarone-induced complications during coronary artery surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Ocular effects in long-term amiodarone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Amiodarone pulmonary toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Amiodarone pulmonary toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Low-dose steroid therapy for prophylaxis of amiodarone-induced pulmonary infiltrates

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Amiodarone--benefits and risks in perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Amiodarone keratopathy: drug-induced lipid storage disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Amiodarone and thyroid function: clinical implications during antiarrhythmic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Effects of amiodarone on thyroid function in patients with ischaemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Iodide excess and thyroid function

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Iodide-induced thyrotoxicosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

Clinical pharmacology and therapeutic applications of the antiarrhythmic agent amiodarone

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2884%2980367-8

7 January 2021

10.1016/S0735-1097(84)80367-8

Identifiers

DOI

1 reference

18 September 2017

1 reference